Drugs / HX044
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06649708 | Dec 2024 → Oct 2025 overdue | high grade malignant neoplasm | Hanx Biopharmaceuticals (Wuhan) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HX044 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06649708 ↗ |